• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

    1/9/24 8:44:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNLI alert in real time by email

    Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022

    Company Closes Financing Round at Nearly $270 Million

    Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors 

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Bekhouche (Investment Corporation of Dubai) and Noubar Afeyan (Flagship Pioneering) to its Board of Directors. As a follow up to the company's initial financing announcement in September 2023, Indigo also announced the final close of its financing round at an expanded raise of nearly $270 million.

    Indigo Ag Logo

    Banks is the former President and CEO of Tyson Foods and a former member of the leadership team at X (an Alphabet company, formerly known as Google [X]), in addition to holding numerous leadership and entrepreneurial roles across the food, agriculture, technology and life sciences industries. He succeeds Ron Hovsepian, who has served as the company's Chief Executive Officer since September 2020. During his tenure, Hovsepian was responsible for successfully producing the world's first crop of registry-issued ag carbon credits at scale, expanding the company's industry-leading biological seed treatments, and the ongoing development and deployment of second-generation digital merchandising solutions. 

    "On behalf of the Board of Directors, I would like to thank Ron for his leadership in taking Indigo to a new level of performance and growth and laying the foundation for its forward path in becoming the undisputed leader in the transformation to regenerative agriculture," said Robert Berendes, Ph.D., Chairman of the Board, Indigo Ag and Executive Partner, Flagship Pioneering. "We are delighted Ron will continue to contribute to Indigo's success as a board member and an advisor to the CEO."

    Berendes continued, "Dean has been a strategic and deeply engaged board member for Indigo, drawing on his extensive experience as an entrepreneur, technologist, innovator, and business executive. He is an energizing leader and visionary, and I am confident he will steward the company into this next critical phase of growth and profitability, and ultimately realize the full potential of the Indigo platform for companies, farmers, and the planet."

    "Dean brings entrepreneurial and operational experience and excellence to Indigo and an extensive track record in building value for life sciences, tech, and food companies, and he joins at an exciting time, given the recent close of the company's latest financing round," said Noubar Afeyan, Founder and CEO of Flagship Pioneering and Co-Founder of Indigo Ag. "His unique background makes him well-positioned to realize Indigo's bold ambitions and also to contribute to Flagship's growing sustainability portfolio."

    "I'm thrilled to take on the role of CEO of Indigo Ag. Over the last year on the board, I have witnessed the tremendous investment we've made to build scientifically validated digital sustainability tools and biological products that farmers, agribusiness, our CPG partners, and our planet urgently need," said Dean Banks, Incoming CEO of Indigo Ag and CEO-Partner of Flagship Pioneering. "Indigo's solutions are delivering on their promise to help make our farmers more successful today, driving higher yields and new revenue streams while helping them nurture their soil for better tomorrows. The company is uniquely positioned as a trusted, independent partner impacting millions of acres today across the agricultural value chain. I look forward to working with the team to take the company to the next level as we scale its growth and impact."

    About Dean Banks

    Banks most recently served as President and CEO of Tyson Foods where he was responsible for charting the long-term vision and transformation plan for the company including integration of advanced technologies like artificial intelligence, robotics, sustainable supply chain solutions and development of alternative proteins throughout its operations. During his four-year tenure with the company, he also served on the Board and executive leadership team.

    Banks joined Tyson from the high-tech incubator at Alphabet, the company formerly known as Google [X], where he served on the leadership team and led moonshot projects across multiple industries including sustainable food (as co-founder of Tidal) and robotics (as co-founder of Intrinsic).

    Banks was previously managing partner of SEED Ventures, a group investing in and developing early-stage healthcare technologies. He also has served as a consultant to Cleveland Clinic Innovations, SVP of Business Development and Strategic Marketing at OrthoHelix, co‐founder and CEO of Connective Orthopedics, and Vice President at Highland Capital Partners. He currently serves on the Boards of Vergent Bioscience (where he was a co-founder and founding CEO), on the Advisory Board of Shiru, and is a Sr. Advisor at Advent International.

    Banks served as a former platoon sergeant and squad leader in the U.S. Marine Corps. He holds a Bachelor of Arts from Miami University and a Master of Business Administration from the Harvard Business School.

    Company Closes Financing Round

    Indigo recently closed a financing round at nearly $270 million. As announced in September 2023, Indigo's funding round included existing investors, led by Flagship Pioneering, and new investors, including the State of Michigan Retirement System, one of the largest pension funds in the U.S. and Lingotto Investment Management, a $3 billion innovation-focused fund owned by Exor N.V., one of Europe's largest diversified holding companies.

    "This latest funding round is a testament to the power of Indigo's platform and positions the company for growth across all aspects of the business, from biologicals to digital to carbon," said Berendes.

    Indigo Adds to Board of Directors

    As members of the board, Nader Bekhouche and Noubar Afeyan bring decades of experience to the company's leadership team and will help Indigo Ag take the next step to deliver meaningful and impactful solutions that turn sustainable practices into value for its farmer, agribusiness, and corporate customers.

    Berendes noted, "I'm thrilled to add these two uniquely skilled leaders to our board. Their addition will further strengthen our board and its ability to quickly and decisively make important decisions that will benefit our farming community, our corporate customers, and the planet."

    Nader Bekhouche is currently heading the Growth Equity investment team at Investment Corporation of Dubai, the principal investment arm of the Government of Dubai, which he joined in 2015. Bekhouche has held many positions in the technology, agriculture and food industries. For the past, four years, he has also served on the board of directors of Inari Agriculture, a company also founded by Flagship Pioneering, which uses its proprietary AI-powered predictive design and multiplex gene editing toolbox to create high performing plant varieties to sustainably improve agriculture.

    "Indigo Ag has ingeniously created solutions to not only maximize the profitability of farming businesses but also to unlock the decarbonization potential of farmland. What Indigo Ag has achieved is a remarkable synthesis that sets it apart — a category of one." said Bekhouche. "It's an intricate combination that others will find incredibly challenging to replicate. I am truly excited to join the Indigo Ag Board at this pivotal juncture. I am looking forward to providing strategic insights and support as Indigo Ag increasingly focuses on profitable growth. The Company's prowess in creating a unique business model positions it as a force with the potential to shape the future of sustainable agriculture."

    Afeyan is founder and CEO of Flagship Pioneering, and a co-founder of Indigo Ag. During his career as inventor, entrepreneur, and CEO, Afeyan has cofounded and helped build over 70 life science and technology companies, including Moderna, and has written numerous scientific publications and is the inventor of over 100 patents.

    Bekhouche and Afeyan will join Berendes, Banks and Hovsepian on the Board of Directors, along with Stéphane Bancel, Andreas Fibig, John Gehring, Geoffrey von Maltzahn, and Deborah Winshel.

    About Indigo Ag

    Indigo Ag is the sustainable agriculture partner that helps farmers and agribusinesses optimize today's yields and profitability, while nourishing the soil for better tomorrows and helping corporations reach their sustainability goals.

    By harnessing science and technology, Indigo Ag's sustainability programs unlock access to high value revenue streams while promoting practices that help land keep its value for future generations. Indigo is currently the only company offering corporations high quality agricultural carbon credits and scope 3 emissions reductions at scale. Our innovative biologicals boost plant growth to help maximize yields, even in tough conditions. And their state-of-the-art digital software facilitates greater efficiency, accuracy and profitability for crop transactions.

    Founded in 2013, Indigo Ag is focused on creating more profitable farmers and more sustainable companies. Operating across 14 countries, the company is delivering on its mission of harnessing nature to help farmers sustainably feed the planet.

    About Flagship Pioneering

    Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics (NASDAQ:DNLI), Foghorn Therapeutics (NASDAQ:FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB) and Tessera Therapeutics.

    Flagship Pioneering Logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dean-banks-appointed-ceo-of-indigo-ag-and-ceo-partner-of-flagship-pioneering-302029919.html

    SOURCE Indigo Ag

    Get the next $DNLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNLI
    $FHTX
    $MCRB
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Denali Therapeutics Inc.
    $DNLI
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Denali Therapeutics Inc.
    $DNLI
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

      Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B-cell depletion using a surrogate for SG299, an in vivo CAR T with CD8-targeted fusogen delivery of a CD19-direc

      5/8/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gallagher Neil

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:04:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Duty Stuart

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:03:21 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Gallagher Neil

      3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:01:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

      4/23/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce

      3/13/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    SEC Filings

    See more
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Sana Biotechnology Inc.

      S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:32:51 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Sana Biotechnology Inc.

      10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:10:02 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care